Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

Andrews, 2021, Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK, medRxiv Singanayagam, 2021, Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study, Lancet Infect Dis Pouwels, 2021, Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK, Nat Med, 10.1038/s41591-021-01548-7 Tartof, 2021, Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study, Lancet, 398, 1407, 10.1016/S0140-6736(21)02183-8 Chemaitelly, 2021, Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar, N Engl J Med, 10.1056/NEJMoa2114114 Bar-On, 2021, Protection of BNT162b2 vaccine booster against COVID-19 in Israel, N Engl J Med, 385, 1393, 10.1056/NEJMoa2114255 Barda, 2021, Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study, Lancet, 10.1016/S0140-6736(21)02249-2 Liu, 2021, Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial, Lancet, 398, 856, 10.1016/S0140-6736(21)01694-9 Nordstrom, 2021, Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic COVID-19 infection in Sweden: a nationwide cohort study, Lancet Reg Health Eur, 10.1016/j.lanepe.2021.100249 Shaw, 2021, Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data, Lancet, 397, 2043, 10.1016/S0140-6736(21)01115-6 Polack, 2020, Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine, N Engl J Med, 383, 2603, 10.1056/NEJMoa2034577 Baden, 2021, Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine, N Engl J Med, 384, 403, 10.1056/NEJMoa2035389 Heath, 2021, Safety and efficacy of NVX-CoV2373 COVID-19 vaccine, N Engl J Med, 385, 1172, 10.1056/NEJMoa2107659 Hulme, 2021, Comparative effectiveness of ChAdOx1 versus BNT162b2 COVID-19 vaccines in health and social care workers in England: a cohort study using OpenSAFELY, medRxiv Deng, 2020, Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques, Science, 369, 818, 10.1126/science.abc5343 Corbett, 2021, Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates, Science, 373, 10.1126/science.abj0299 Hall, 2021, SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN), Lancet, 397, 1459, 10.1016/S0140-6736(21)00675-9 Feng, 2021, Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection, Nat Med, 27, 2032, 10.1038/s41591-021-01540-1 Tan, 2021, Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients, Cell Rep, 34, 10.1016/j.celrep.2021.108728 Tarke, 2021, Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals, Cell Rep Med, 2 Geers, 2021, SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients, Sci Immunol, 6, 10.1126/sciimmunol.abj1750 Stuart ASV, Shaw RH, Liu X, et al. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. Lancet (in press). Atmar, 2021, Heterologous SARS-CoV-2 booster vaccinations—preliminary Report, medRxiv Li, 2021, Heterologous prime-boost immunization with CoronaVac and Convidecia, medRxiv Flaxman, 2021, Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002), Lancet, 398, 981, 10.1016/S0140-6736(21)01699-8 Falsey, 2021, SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3, N Engl J Med, 385, 1627, 10.1056/NEJMc2113468 Choi, 2021, Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis, Nat Med, 27, 2025, 10.1038/s41591-021-01527-y Parry, 2021, Extended interval BNT162b2 vaccination enhances peak antibody generation in older people, medRxiv Sallusto, 2010, From vaccines to memory and back, Immunity, 33, 451, 10.1016/j.immuni.2010.10.008